Director, Business Intelligence, PNH

Opportunity awaits those up to the challenge of developing transformative therapies across a broad range of debilitating diseases.

Summary

We are seeking a talented and energetic Director, Business Intelligence (BI) – EMPAVELI who will play a key role in the commercialization of EMPAVELI in PNH. The Director will be accountable for partnering closely with U.S. commercial, and cross-functional teams to generate market-specific insights from sales and performance analytics and primary market research, to create integrated, actionable insights for cross-functional stakeholder groups across the organization. The ideal candidate must have significant experience working in a commercial insights and analytics position within a biotech or biopharma company, focusing on rare diseases (hematology a plus). The Director will report to the Senior Director, Business Intelligence & Commercial Operations – EMPAVELI, and is expected to drive market knowledge and insights that foster cross-functional action, shaping strategy and tactical execution for EMPAVELI in PNH in the US.

Roles and Responsibilities

• Own brand performance/sales analytics/reporting, including national and subnational analyses
• Partner with the brand lead and relevant cross-functional stakeholders to design and execute strategic primary market research to track brand performance/address key business questions
• BI lead for strategic brand initiatives (e.g., brand planning, tactical planning), providing market outlooks, situation assessments, and SWOT analyses
• Develop expert knowledge across the therapeutic area, including but not limited to competitive landscape (marketed and pipeline), market dynamics, customer behavior, and sentiment
• Partner with Forecasting and maintain a strong understanding of the forecast and provide/validate assumptions that inform the brand forecast
• Proactively scope key business questions, generate hypotheses, independently design studies/analyses, and generate insights for the business with a strong focus on foresight
• Own the annual insights budget for EMPAVELI in PNH

Qualifications

• B.S. degree required (business, biology, or medicine-related degree preferred); advanced Degree (MBA, PhD, PharmD) preferred
• 10+ years in an insights and analytics function within a biotech or biopharma organization

Must-Haves

• Hands-on strong analytics and modeling skills in Excel; familiarity with BI tools such as Power BI
• Experience in rare disease
• Expertise with claims, EMR, and registry datasets to generate strategic/actionable insights
• Expertise in qualitative and quantitative market research methodologies
• Excellent project and vendor management skills; ability to run multiple cross-disciplinary projects simultaneously (e.g., sales analytics, claims analyses, market research) with competing timelines
• Excellent cross-functional collaboration and leadership skills; ability to influence across several levels of the organization, including executive leadership, without authority
• Strategic and analytical mindset; strong problem‑solving/framing abilities
• Excellent communication skills; able to integrate insights from multiple sources, create simplicity from complexity, and articulate compelling solution‑driven narratives that foster action
• Managerial courage: ability to challenge and persuade different/cross‑functional audiences within the organization, including business and executive leadership
• Seasoned in commercial assessments, asset evaluation, and prioritization

Employment

Full-Time Regular Domestic retravel may be required in this role (up to 20%)

Work Arrangement

Hybrid

Travel Requirements

Domestic retravel may be required in this role (up to 20%)

Education

Bachelor's Degree

Benefits and Perks

• Apellis offers a comprehensive benefits package, inclusive flexible time off, summer and winter shutdowns, paid family leave and more!

Company Background

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life‑changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3‑targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first‑ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC‑MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on LinkedIn and X.

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life‑changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3‑targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first‑ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC‑MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on LinkedIn and X.

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life‑changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3‑targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first‑ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC‑MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on LinkedIn and X.

Other Duties

Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice.

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life‑changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3‑targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first‑ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC‑MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on LinkedIn and X.

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life‑changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3‑targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first‑ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC‑MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on LinkedIn and X.

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life‑changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3‑targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first‑ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC‑MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on LinkedIn and X.

#J-18808-Ljbffr Jobleads-US